

requests for information on highly technical matters and matters of scientific and public policy related to health resources and policy.

Systems Technology Office (NYC, formerly HNYC). (1) Focuses on those systems that impact health—from physiologic systems (e.g., immune) to the healthcare system and everything in between. (2) Speeds progress in the integration of systems, including and especially technological approaches to doing so. (3) Advises the ARPA–H Director on matters concerning ARPA–H-sponsored research activities related to health systems technology. (4) Responds to requests for information on highly technical matters and matters of scientific and public policy related to health systems technology.

Equity and Inclusion Office (NYD, formerly HNYD). (1) Coordinates, facilitates, and supports programs to ensure equity, diversity, and inclusion in all aspects of ARPA–H's work. (2) Provides strategic and programmatic leadership for ARPA–H's efforts to reduce health disparities and foster health equity in biomedical research. (3) Evaluates ARPA–H's progress towards achieving greater diversity and health equity in biomedical and health research. (4) Promotes ARPA–H efforts to build a diverse cohort of collaborators, staff, performers, and others.

Strategic Planning, Evaluation, and Analytics Office (NYE, formerly HNYE). (1) Oversees ARPA–H-wide planning, evaluation, and analysis/analytic activities. (2) Advises ARPA–H leadership and staff on all aspects of strategic planning, reporting, and operational effectiveness for ARPA–H activities. (3) Provides leadership and guidance to ARPA–H's business community in the development and oversight of a strategic administrative management plan, goals, organizational effectiveness and business analytics. (4) Oversees the development of analytic and evaluation strategies to drive greater efficiency and effectiveness in administrative and programmatic operations.

Innovation and Entrepreneurship Office (NYF, formerly HNYF). (1) Inspires innovation and creativity throughout ARPA–H, including stimulating the culture of innovation, ideation, and dynamic thinking and leveraging design research and design thinking. (2) Promotes practical strategies to provide resources for programs and projects to incorporate and implement transition principles to inform innovation in overall ARPA–H commercialization strategies. (3) Serves as the ARPA–H focal point for the

management of all Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Program activities, and implementation of pertinent legislation, rules and regulations and associated matters related to the SBIR/STTR Program. (4) Proposes and implements innovative strategies to promote the commercialization of innovative high impact technologies including research tools, medical devices, and therapeutics throughout the program development and management lifecycle. (5) Assesses the commercial potential of ARPA–H technology priorities and provides guidance on how best to structure programs, projects, and goals for successful transition.

Delegations of Authority: All delegations and redelegations of authority to officers and employees of NIH that were in effect immediately prior to the effective date of this amendment and are consistent with this amendment shall continue in effect, pending further redelegation.

Dated: May 24, 2022.

Xavier Becerra,

Secretary, U.S. Department of Health and Human Services.

[FR Doc. 2022–11519 Filed 5–25–22; 4:15 pm]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Frederick National Laboratory Advisory Committee to the National Cancer Institute.

The meeting will be held virtually and is open to the public. Individuals who plan to view the virtual meeting and need special assistance or other reasonable accommodations to view the meeting, should notify the Contact Person listed below in advance of the meeting. The meeting will be videocast and can be accessed from the NIH Videocasting and Podcasting website (<http://videocast.nih.gov>).

Name of Committee: Frederick National Laboratory Advisory Committee to the National Cancer Institute.

Date: June 27, 2022.

Time: 11:00 a.m. to 2:00 p.m.

Agenda: Ongoing and new activities at the Frederick National Laboratory for Cancer Research.

Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Rockville, MD 20850 (Virtual Meeting).

Contact Person: Wlodek Lopaczynski, M.D., Ph.D., Assistant Director, Office of the Director, Division of Extramural Activities, National Cancer Institute, National Institutes of Health, 9609 Medical Center Drive, Seventh Floor, West Tower, Room 7W514, Bethesda, MD 20892, (240) 276–6458, lopacw@mail.nih.gov.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute's/Center's home page: FNLAC: <https://deainfo.nci.nih.gov/advisory/fac/fac.htm>, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: May 24, 2022.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2022–11458 Filed 5–26–22; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Human Genome Research Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Inherited Disease Research Access Committee.

Date: July 8, 2022.

Time: 11:30 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.